Akt Activators are a diverse array of chemical compounds that indirectly promote the functional activity of the protein Akt through modulation of various cellular signaling pathways. Forskolin, by elevating cAMP levels, indirectly stimulates Akt through PKA activation, which can phosphorylate regulatory proteins that might affect Akt signaling positively. Ionomycin increases intracellular calcium, which could trigger the activation of calcium-dependent protein kinases, facilitating the activation of Akt or related pathways. The PI3K inhibitor LY294002 might enhance Akt activity by disrupting negative feedback loops, while U0126, a MEK inhibitor, could favor Akt activation by reducing competitive MAPK/ERK signaling. Sunitinib's inhibition of tyrosine kinases may allow for enhanced Akt activity by mitigating negative regulatory effects from these pathways. Additionally, the modulation of cellular redox states by N-acetylcysteine could create conditions favoring Akt activation.
Other chemicals contribute to the indirect activation of Akt through metabolic modifications and alterations in gene expression. AICAR, an AMPK activator, induces metabolic shifts that can impact Akt, with AMPK's influence on mTOR signaling potentially facilitating Akt activation. Rosiglitazone, as a PPARγ agonist, may enhance Akt activity by modulating related gene expression networks. Epigallocatechin gallate's kinase-inhibiting properties may reduce competitive signaling, leading to an indirect increase in Akt activation. PMA's activation of PKC, along with SB203580's inhibition of p38 MAPK, can alter signaling pathways intersecting with Akt, which may enhance its activation. Furthermore, TrichostatinA, as a histone deacetylase inhibitor, may influence the expression of proteins that regulate Akt, thus potentially impacting Akt's activation indirectly. Collectively, these chemical activators, through their targeted effects on various signaling pathways and cellular processes, support the enhancement of Akt-mediated functions, demonstrating the complex interplay of intracellular signaling and its influence on Akt activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. Elevated calcium can activate calmodulin-dependent kinase (CaMK), which may indirectly lead to the activation of Akt through phosphorylation events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter the downstream AKT signaling pathway. By inhibiting PI3K, LY294002 may reduce negative feedback loops, potentially allowing for an increase in Akt activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that can shift the balance of signaling through the MAPK/ERK pathway. By inhibiting MEK, U0126 may indirectly enhance Akt activation by reducing crosstalk that inhibits Akt. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a tyrosine kinase inhibitor that might indirectly increase Akt activity by reducing competition from other tyrosine kinase signaling pathways that can negatively regulate Akt. | ||||||
N-Acetyl-L-cysteine | 616-91-1 | sc-202232 sc-202232A sc-202232C sc-202232B | 5 g 25 g 1 kg 100 g | $34.00 $74.00 $270.00 $114.00 | 34 | |
N-acetylcysteine modulates cellular redox states, which can affect signaling pathways intersecting with Akt's regulation, potentially leading to enhanced Akt activation. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR activates AMP-activated protein kinase (AMPK), which can lead to metabolic changes influencing Akt activity. AMPK activation can also alter mTOR signaling, a pathway closely linked to Akt activation. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone is a PPARγ agonist that can alter gene expression patterns, influencing signaling pathways that may intersect with Akt's regulatory network, possibly leading to enhanced Akt activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate inhibits multiple kinases, which could result in reduced competitive signaling and indirectly enhance Akt activation by altering the cellular signaling landscape. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is an activator of protein kinase C (PKC), which can modulate the signaling pathways that intersect with Akt, potentially enhancing its activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, which can shift signaling dynamics to favor pathways that activate Akt, indirectly leading to enhanced Akt activity. | ||||||